The use of PEG-IFN plus RBV treatment for AHC within 6 months of diagnosis is now recommended for HIV-1 co-infected cases [17]–[19] although data on the response of HIV-1 infected individuals with AHC to the PEG-IFN plus RBV remain limited. Here, IFNA1 is linked to alternating hemiplegia of childhood.